Direct tumor injection trial halted early for advanced cancers
NCT ID NCT04387071
Summary
This early-phase trial tested whether injecting two immune-stimulating drugs directly into tumors could help control advanced cancers, including pancreatic cancer. The goal was to see if this approach could slow tumor growth by rallying the patient's own immune system to attack the cancer. The study was terminated early after enrolling only two participants, so its effectiveness remains unknown.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hoag Memorial Hospital
Newport Beach, California, 92663, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Lucile Packard Children's Hospital Stanford University
Palo Alto, California, 94304, United States
-
USC / Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
Explore the condition pages connected to this study.